Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Investigator Global Assessment Scale (IGA) Score Change [ Time Frame: 8 Weeks ]
Achievement of an IGA score of 'clear' or 'almost clear' plus a 2-grade improvement from Baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4).
Secondary Outcome Measures :
IGA Score Change [ Time Frame: Baseline, Week 2 and Week 4 ]
Achievement of an IGA score of 'clear' or 'almost clear' plus a 2-grade improvement from Baseline at weeks 2 and 4. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4).
Overall Assessment of Erythema Score [ Time Frame: Baseline, Week 2, Week 4, Week 8 ]
Change from Baseline in Overall Assessment of Erythema score at each study visit. Achievement of an Overall Assessment of Erythema score of 0 or 1 plus a 2-grade improvement from Baseline. This assessment scale has four severity grades reported from 0-3 and defined as None (0), Mild (1), Moderate (2), Severe (3).
Overall Assessment of Scaling Score [ Time Frame: Baseline, Week 2, Week 4, Week 8 ]
Change from Baseline in Overall Assessment of Scaling score at each study visit. Achievement of an Overall Assessment of Scaling score of 0 or 1 plus a 2-grade improvement from Baseline. This assessment scale has four severity grades reported from 0-3 and defined as None (0), Mild (1), Moderate (2), Severe (3).
Change in WI-NRS pruritus score from Baseline. In subjects with a Baseline WI-NRS pruritis score of > 6, achievement of a > 4-point improvement from Baseline. WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch")
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Participants legally competent to sign and give informed consent.
Males and females ages 18 years and older (inclusive) at the time of consent.
Clinical diagnosis of seborrheic dermatitis of at least 3 months duration as determined by the Investigator. Stable disease for the past 4 weeks.
Seborrheic dermatitis of the scalp and/or face and/or trunk and/or intertriginous areas
An Investigator Global Assessment (IGA) of disease severity of at least Moderate ('3') at Baseline.
Overall Assessment of Erythema and Overall Assessment of Scaling scores of Moderate ('2') at Baseline.
Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2).
Females of non-childbearing potential must either be post-menopausal with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.
Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.
Subjects are considered reliable and capable of adhering to the Protocol and visit schedule according to the Investigator judgment.
Subjects who cannot discontinue treatment with therapies for the treatment of seborrheic dermatitis prior to the Baseline visit and during the study according to Excluded Medications and Treatments
Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED
Subjects who cannot discontinue the use of strong P-450 cytochrome inhibitors e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, suboxone and telithromycin for two weeks prior to the Baseline visit (Visit 2) and during the study
Subjects who cannot discontinue the use of strong P-450 cytochrome inducers e.g., efavirenz, nevirapine, glucocorticoids, barbiturates (including phenobarbital), phenytoin, rifampin, and carbamazepine for two weeks prior to the Baseline visit (Visit 2) and during the study.
Subjects with PHQ-8 >10 at Screening or Baseline visits.
Previous treatment with ARQ-151 and ARQ-154.
Subjects who have received oral roflumilast (Daliresp®, Daxas®) or other PDE-4 inhibitors (apremilast) within the past 4 weeks
History of and/or concurrent condition of serious hypersensitivity (anaphylactic shock or anaphylactoid reaction) to PDE-4 inhibitors.
Known allergies to excipients in ARQ-154 foam
Known or suspected:
severe renal insufficiency or moderate to severe hepatic disorders
hypersensitivity to component(s) of the investigational products
history of severe depression, suicidal ideation
Subjects with a history of a major surgery within 8 weeks prior to Baseline (Visit 2) or has a major surgery planned during the study
Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.
Subjects unable to apply product to the scalp due to physical limitations.
Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
A clinically relevant history of abuse of alcohol or other drugs, at the discretion of the Investigator.
Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects.
Any condition that in the Investigator's assessment would preclude the subject from participating in the study.